AR and prostate cancer: The antitumor action of MLT in prostate cancer cell lines has been attributed to changes in cell cycle, androgen receptor (AR) translocation, and inhibition of angiogenesis through reduced expression of factors that act under hypoxic conditions, such as hypoxia-inducible factor 1α (HIF-1α) [18–25].